Last $65.87 USD
Change Today -0.47 / -0.71%
Volume 3.8M
STJ On Other Exchanges
New York
As of 8:04 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

One St. Jude Medical Drive

Saint Paul, MN 55117

United States

Phone: 651-756-2000

Fax: 651-756-3301

abling in the cardiac catheterization laboratory. Physicians could remove the device's handle and insert a stent delivery system directly through the PressureWire Aeris, eliminating the time and cost of using an additional, traditional guidewire. The company announced CE Mark approval for the EnligHTN Renal Denervation System in 2012. This renal denervation technology includes an ablation catheter, ablation generator, and guiding catheter. The EnligHTN renal denervation ablation catheter is a multi-electrode ablation technology that features a non-occlusive basket design that delivers a predictable pattern of four evenly-spaced transmural lesions with each catheter placement. The company launched EnligHTN outside of the United States with focus in select countries in Europe and in Australia. Its AMPLATZER Vascular Plugs are expandable, cylindrical devices made from Nitinol wire that reduce, redirect or eliminate blood flow to unwanted blood vessels. During 2012, it received FDA clearance (FDA clearance in 2012 and European CE Mark approval) for AMPLATZER Vascular Plug 4 (AVP 4). The lower-profile AVP 4 extends the reach of the AMPLATZER vascular plug family to smaller and often more distal blood vessels. The company’s AMPLATZER Vascular Plugs are designed for use in abnormal blood vessels outside the heart, below the neck, and above the knee and utilize standard delivery systems used by interventional radiologists and vascular surgeons in these procedures. The company’s structural heart valve products facilitate blood flow from the chambers of the heart throughout the entire body. The company markets both the Epic and Biocor porcine stented tissue heart valves. It received European CE Mark approval for the Trifecta tissue heart valve, marking its expansion into the pericardial aortic stented tissue valve market. FDA approval for the Trifecta tissue valve was launched in Japan in 2012. This next-generation tissue valve has a tri-leaflet stented pericardial design, which offers hemodynamic performance (the optimization of blood flow through the valve) that mimics as closely as possible the flow of a natural, healthy heart valve. The company also offers a complement of heart valve repair products, including two fully flexible and two semi-rigid rings, such as the Tailor flexible ring and the Attune flexible adjustable annuloplasty ring, and the SJM Séguin Semi-Rigid Ring and the SJM Rigid Saddle Ring. Annuloplasty rings are prosthetic devices used to repair diseased or damaged mitral and tricuspid heart valves. Building upon the company’s experience in the surgical heart valve market, the company developed the Portico transcatheter aortic valve for a minimally invasive alternative to open heart surgery. Its transcatheter heart valve is designed to increase physician control and accuracy during valve deployment. The Portico transcatheter 23 mm aortic valve and the transfemoral delivery system received European CE Mark approval in 2012. The company is in the process of planning a U.S. IDE trial to evaluate the safety and efficacy of the Portico transcatheter aortic valve and delivery systems for patients with symptomatic severe aortic stenosis and who are considered at high or extreme risk for open-heart surgery. The company offers a line of products for the treatment of the two common categories of heart defects, such as congenital defects consisting primarily of holes in the septum between the right and left sides of the heart; and device closure that might reduce the risk of ischemic stroke in patients with AF and in patients with PFO. The company’s congenital defect products include the AMPLATZER Septal Occluder for closure of atrial septal defects (FDA and European CE Mark approvals), the AMPLATZER Muscular VSD Occluder for closure of muscular ventricular septal defects (FDA and European CE Mark approvals), and the AMPLATZER Duct Occluder for closure of patent ductus arteriosus (FDA and European CE Mark approvals). These devices are introduced through a small catheter that is inserted into the groin and advanced to the heart. Transcatheter closure offers pediatric and adult patients a minimally invasi


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STJ:US $65.87 USD -0.47

STJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $14.81 USD -0.04
CR Bard Inc $171.03 USD -5.91
Smith & Nephew PLC 1,191 GBp -9.00
Terumo Corp ¥2,941 JPY +35.00
Zimmer Holdings Inc $112.10 USD -0.42
View Industry Companies

Industry Analysis


Industry Average

Valuation STJ Industry Range
Price/Earnings 19.0x
Price/Sales 3.4x
Price/Book 4.5x
Price/Cash Flow 17.3x
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at